Unaudited Financial Results by the Board and approval of CCL ESOS 2025 terms and conditions by the nomination and remuneration committee u/r 5(3) of SEBI (Share Based Employee Benefits ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Crescentis Capital (NBFC) reported a strong turnaround for Q3 FY26 (quarter ended Dec 31, 2025), with total revenue from operations of ₹371.95 lakhs compared to a loss of ₹426.76 lakhs in Q3 FY25. Profit after tax for the quarter stood at ₹119.27 lakhs, against a loss of ₹428.65 lakhs a year ago. For the nine-month period, revenue jumped to ₹892.76 lakhs (from ₹70.50 lakhs) and PAT surged to ₹482.51 lakhs (from a loss of ₹164.35 lakhs), driven mainly by net gains on fair value changes (₹693.74 lakhs for 9M) and interest income following the start of lending operations in June 2025. The board also approved the CCL Employees' Stock Option Scheme 2025, subject to regulatory approvals. The Rights Issue of ₹4,903.91 lakhs raised in July 2025 has been fully utilised as per stated objects. Statutory auditor D.S. Talwar & Co issued an unqualified limited review report.
Sharp swing from loss to profit and oversubscription of the recent rights issue signal improving fundamentals, though a large portion of the gain comes from fair value changes in investments rather than core lending income. The new ESOS scheme could cause future dilution, and the pledged securities of ₹2,045.30 lakhs indicate leverage for the loan-against-securities book.